Heart Disease & Cardiology Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

This Phase 3 study is exploring the medicine CagriSema for adults who have both high blood pressure and obesity. The goal is to find out if this treatment can safely lower blood pressure while also helping with weight control. If successful, CagriSema could provide a new option that addresses these two related health challenges together, potentially improving overall heart health for many people.

A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease

This upcoming Phase 3 trial will test enicepatide, a new type of medicine, in adults who are overweight or obese and have cardiovascular disease. The study aims to see if enicepatide can reduce the risk of serious heart problems in this group. With plans to include over 8,000 participants, this research could lead to a new way to protect heart health in people struggling with excess weight and heart disease.

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

This Phase 3 trial evaluated semaglutide, a once-weekly injection, for people living with heart failure with preserved ejection fraction, obesity, and type 2 diabetes. The study included more than 600 participants and has now completed, with results available. If semaglutide proves effective, it may help improve heart failure symptoms and reduce body weight, offering a meaningful improvement in quality of life for people managing these common conditions.

Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

This Phase 3 study examined two oral antidiabetic drugs, dapagliflozin and semaglutide, in patients who experienced a specific type of heart attack called ST-segment elevation myocardial infarction. The research aimed to see if these medications could lower inflammation after a heart attack, which might help patients recover better and reduce future heart problems. Conducted in Mexico with 44 participants, the study results are still pending and will provide important information about recovery after heart attacks.

Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery

This Phase 4 pilot trial is set to test an oral drug called roxadustat in patients undergoing off-pump coronary artery bypass surgery for coronary artery disease. The goal is to find out if roxadustat can reduce heart muscle injury or prevent heart attacks during the recovery period after surgery. This smaller study in China plans to enroll 80 patients and could lead to ways to improve outcomes after heart surgeries.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.